UCB BIOPHARMA SRL

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

Phase 3

Recruiting

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Zilucoplan

First Posted Date: 2024-06-24

Last Posted Date: 2024-12-06

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 25

Registration Number: NCT06471361

Locations: 🇬🇧
Dv0013 40760, Oxford, United Kingdom
🇺🇸
Dv0013 50628, New Haven, Connecticut, United States
🇺🇸
Dv0013 50634, Tampa, Florida, United States

and more 8 locations

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Phase 3

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Zilucoplan

First Posted Date: 2024-05-30

Last Posted Date: 2024-12-03

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 8

Registration Number: NCT06435312

Locations: 🇺🇸
Mg0015 50574, Denton, Texas, United States
🇮🇹
Mg0015 40144, Milano, Italy
🇰🇷
Mg0015 20104, Seoul, Korea, Republic of

and more 2 locations

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: bimekizumab
Drug: placebo
Drug: ustekinumab

First Posted Date: 2024-05-22

Last Posted Date: 2024-07-26

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 168

Registration Number: NCT06425549

Locations: 🇺🇸
Ps0021 50196, Northridge, California, United States
🇺🇸
Ps0021 50161, Los Angeles, California, United States
🇺🇸
Ps0021 50599, Kew Gardens, New York, United States

and more 4 locations

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

Phase 1

Active, not recruiting

Conditions: Healthy Participants

Interventions: Drug: UCB9741
Drug: Placebo

First Posted Date: 2024-03-18

Last Posted Date: 2024-12-06

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 40

Registration Number: NCT06315335

Locations: 🇺🇸
Up0118 10001, Glendale, California, United States

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase 3

Recruiting

Conditions: Childhood Absence Epilepsy
Juvenile Absence Epilepsy

Interventions: Drug: Brivaracetam Film-coated tablet
Drug: Brivaracetam oral solution

First Posted Date: 2024-03-18

Last Posted Date: 2024-12-06

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 120

Registration Number: NCT06315322

Locations: 🇺🇸
Ep0224 50640, Winston-Salem, North Carolina, United States
🇮🇹
Ep0224 40629, Roma, Italy
🇺🇸
Ep0224 50140, Birmingham, Alabama, United States

and more 12 locations

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: brivaracetam (BRV) tablet
Drug: brivaracetam (BRV) dry syrup

First Posted Date: 2024-03-15

Last Posted Date: 2024-07-31

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 64

Registration Number: NCT06312566

Locations: 🇯🇵
EP0231 1, Sumida-ku, Japan

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Phase 2

Recruiting

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: rozanolixizumab

First Posted Date: 2023-11-29

Last Posted Date: 2024-12-06

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 12

Registration Number: NCT06149559

Locations: 🇵🇱
Mg0006 40734, Lodz, Poland
🇨🇳
Mg0006 20081, Taipei City, Taiwan
🇮🇹
Mg0006 40144, Milano, Italy

and more 3 locations

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

Phase 2

Recruiting

Conditions: Parkinson Disease

Interventions: Drug: UCB0022
Other: Placebo

First Posted Date: 2023-09-28

Last Posted Date: 2024-12-02

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 189

Registration Number: NCT06055985

Locations: 🇺🇸
Pd0060 50586, Louisville, Kentucky, United States
🇺🇸
Pd0060 50506, Phoenix, Arizona, United States
🇺🇸
Pd0060 50590, Scottsdale, Arizona, United States

and more 66 locations

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Phase 2

Recruiting

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Zilucoplan

First Posted Date: 2023-09-28

Last Posted Date: 2024-11-22

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 8

Registration Number: NCT06055959

Locations: 🇺🇸
Mg0014 50168, Chicago, Illinois, United States
🇺🇸
Mg0014 50574, Denton, Texas, United States
🇮🇹
Mg0014 40144, Milano, Italy

and more 3 locations

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Active, not recruiting

Conditions: Chronic Plaque Psoriasis
Moderate to Severe Chronic Plaque Psoriasis

Interventions: Other: Placebo
Drug: Bimekizumab

First Posted Date: 2023-08-25

Last Posted Date: 2024-08-23

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 133

Registration Number: NCT06011733

Locations: 🇨🇳
Ps0041 20308, Shanghai, China
🇨🇳
Ps0041 20117, Guangzhou, China
🇨🇳
Ps0041 20310, Ningbo, China

and more 15 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy